Reviewer's report
Title:Multicenter Comparison of PEG-IFN 2a or 2b Plus Ribavirin for
Treatment-naive HCV Patient in Korean Population
Version: 2Date:5 March 2013
Reviewer: Eckart Schott
Reviewer's report:
I feel that the authors have addressed most of the reviewers' concerns
adequately. There remain a few concerns that should be addressed before the
article can be published:
• Page 14, 2nd paragraph: it is not clear, which value relates to which treatment
arm or to RVR/no-RVR, respectively.
• Page 22, 1st paragraph: No further clinial trials will be conducting with dual
treatment of interferon/ribavirin. The sentence should be deleted.
• The statistics in table 4 still need to be clarified: The authors explain in their
rebuttal letter that they compared the frequency of grade 1-2 with the frequency
of grade 3 AEs (p=0.23). However, the legend to the table states that p=0.23
stands for the comparison of IFNa2a vs. IFNa2b. Which is correct? If it is for
IFNa2a vs IFNa2b, does the p apply to the comparison of grade 1/2 side effects
or of grade 3 side effects?
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have received lecture fees, travel support and compensation for advisory
boards from Roche and MSD.
Reviewer's report
Title:Multicenter Comparison of PEG-IFN 2a or 2b Plus Ribavirin for
Treatment-naive HCV Patient in Korean Population
Version: 2Date:5 March 2013
Reviewer: Eckart Schott
Reviewer's report:
I feel that the authors have addressed most of the reviewers' concerns
adequately. There remain a few concerns that should be addressed before the
article can be published:
• Page 14, 2nd paragraph: it is not clear, which value relates to which treatment
arm or to RVR/no-RVR, respectively.
• Page 22, 1st paragraph: No further clinial trials will be conducting with dual
treatment of interferon/ribavirin. The sentence should be deleted.
• The statistics in table 4 still need to be clarified: The authors explain in their
rebuttal letter that they compared the frequency of grade 1-2 with the frequency
of grade 3 AEs (p=0.23). However, the legend to the table states that p=0.23
stands for the comparison of IFNa2a vs. IFNa2b. Which is correct? If it is for
IFNa2a vs IFNa2b, does the p apply to the comparison of grade 1/2 side effects
or of grade 3 side effects?
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have received lecture fees, travel support and compensation for advisory
boards from Roche and MSD.
Please review this paper.
user
Reviewer's report
Title:Multicenter Comparison of PEG-IFN 2a or 2b Plus Ribavirin for
Treatment-naive HCV Patient in Korean Population
Version: 2Date:5 March 2013
Reviewer: Eckart Schott
Reviewer's report:
I feel that the authors have addressed most of the reviewers' concerns
adequately. There remain a few concerns that should be addressed before the
article can be published:
• Page 14, 2nd paragraph: it is not clear, which value relates to which treatment
arm or to RVR/no-RVR, respectively.
• Page 22, 1st paragraph: No further clinial trials will be conducting with dual
treatment of interferon/ribavirin. The sentence should be deleted.
• The statistics in table 4 still need to be clarified: The authors explain in their
rebuttal letter that they compared the frequency of grade 1-2 with the frequency
of grade 3 AEs (p=0.23). However, the legend to the table states that p=0.23
stands for the comparison of IFNa2a vs. IFNa2b. Which is correct? If it is for
IFNa2a vs IFNa2b, does the p apply to the comparison of grade 1/2 side effects
or of grade 3 side effects?
Level of interest: An article of importance in its field
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I have received lecture fees, travel support and compensation for advisory
boards from Roche and MSD.
assistant